SynthesisHuman vaccines & immunotherapeutics2013
Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.
Synthesis in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05996549 (Acceptability, Cost-Effectiveness, and Capacity of a Facility-Based Seasonal Influenza Vaccination), which is not on this map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acceptability, Cost-Effectiveness, and Capacity of a Facility-Based Seasonal Influenza Vaccination: A Study in Selected Hospitals of Bangladesh
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Facilitators and barriers to maternal immunization and strategies to improve uptake in low-income and lower-middle income countries: A systematic review.Human vaccines & immunotherapeutics · 2024Pooled it
- Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.PLoS medicine · 2024Pooled it
- Drivers of and barriers to routine adult vaccination: A systematic literature review.Human vaccines & immunotherapeutics · 2022Pooled it
- Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic reviewRevista espanola de salud publica · 2018Pooled it
- The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.American journal of preventive medicine · 2018Pooled it
- Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.Drug safety · 2018Trial
- Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice.NPJ vaccines · 2025Article
- Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.Vaccine · 2024Article
- Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh.Journal of global health · 2024Article
- Incidence of Hospitalization due to Influenza-Associated Severe Acute Respiratory Infection During 2010-2019 in Bangladesh.Influenza and other respiratory viruses · 2024Article
- Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh.BMC public health · 2024Article
- A Knockout of the IFITM3 Gene Increases the Sensitivity of WI-38 VA13 Cells to the Influenza A Virus.International journal of molecular sciences · 2024Article
- The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- Article
- A review of policies and coverage of seasonal influenza vaccination programs in the WHO Eastern Mediterranean Region.Influenza and other respiratory viruses · 2023Review
- Article
- Seasonal Influenza Vaccine Intention among Nurses Who Have Been Fully Vaccinated against COVID-19: Evidence from Greece.Vaccines · 2023Article
- Costs of seasonal influenza vaccination in South Africa.Influenza and other respiratory viruses · 2022Review
- Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesEconomic evaluations on influenza vaccination from low resource settings are scarce and have not been evaluated using a systematic approach. Our objective was to conduct a systematic review on the value for money of influenza vaccination in low- and middle-income countries.
methodsPubMed and EMBASE were searched for economic evaluations published in any language between 1960 and 2011. Main outcome measures were costs per influenza outcome averted, costs per quality-adjusted life years gained or disability-adjusted life years averted, costs per benefit in monetary units or cost-benefit ratios.
resultsNine economic evaluations on seasonal influenza vaccine met the inclusion criteria. These were model- or randomized-controlled-trial (RCT)-based economic evaluations from middle-income countries. Influenza vaccination provided value for money for elderly, infants, adults and children with high-risk conditions. Vaccination was cost-effective and cost-saving for chronic obstructive pulmonary disease patients and in elderly above 65 y from model-based evaluations, but conclusions from RCTs on elderly varied.
conclusionEconomic evaluations from middle income regions differed in population studied, outcomes and definitions used. Most findings are in line with evidence from high-income countries highlighting that influenza vaccine is likely to provide value for money. However, serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middle income countries. Evidence on cost-effectiveness from low-income countries is lacking altogether, and more information is needed from full economic evaluations that are conducted in a standardized manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.